Francis Knuettel II's Form 4 filing

Pelthos Therapeutics Inc. (PTHS) · filed May 26, 2026

Accession no.: 0001919246-26-000081
Filed: May 26, 2026
Trade date: May 22, 2026
Filing delay: 4 days
Rule 10b5-1 plan: Not checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $40.3K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Francis Knuettel IICIK 0001433316	Officer (CFO, Treas & Secty)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
May 22, 2026	Common Stock	DReturned to the companyDisposed	−13,947	$0.00^F1	$0	19,525	Direct
May 22, 2026	Common Stock	SSaleDisposed	−1,500	$26.84^F3	−$40,260	11,316	Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade date	Security	Transaction	Underlying shares	Unit price	Value	Held after	Ownership	Flags
May 22, 2026	Common Stock	AGrant or awardAcquired	+59,500	–^F5	–	59,500	Direct
May 22, 2026	Common Stock	DReturned to the companyDisposed	−42,500	–^F6	–	0	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

Represents the forfeiture and cancellation of unvested restricted stock units ("RSUs") of Pelthos Therapeutics Inc. (the "Issuer"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the "Separation Agreement") in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

Referenced by the price of 1 transaction in Table I.

Represents an open market sale of the Lara Knuettel Revocable (the "Trust") on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected

Referenced by the price of 1 transaction in Table I.

Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement.

Referenced by the price of 1 transaction in Table II.

Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

Referenced by the price of 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)